STOCKS TELEGRAPH

Tag: NASDAQ: XERS

  • Is XERS Stock a Good Buy in 2025? Key Insights for Investors

    Is XERS Stock a Good Buy in 2025? Key Insights for Investors

    Xeris Biopharma Holdings (NASDAQ: XERS) has been gaining attention in the biotech industry due to its innovative drug pipeline and strong growth potential. As investors look toward 2025, many are wondering: Is XERS stock a good buy in 2025? This article explores Xeris’ business model, financials, growth drivers, risks, and expert opinions to help you determine if it’s a solid investment.

    Xeris Biopharma Overview & Business Model

    Xeris Biopharma is a biotech company specializing in ready-to-use injectable drug formulations that improve patient adherence and reduce the need for refrigeration. Its proprietary XeriSol™ and XeriJect™ technology platforms enhance the stability and delivery of various biologics and small molecules.

    Key Revenue Sources:

    • Gvoke HypoPen (glucagon for severe hypoglycemia treatment)
    • Keveyis (the first FDA-approved treatment for primary periodic paralysis)
    • Recorlev (for Cushing’s syndrome)
    • Partnerships and licensing agreements with pharmaceutical companies

    XERS Stock Performance & Financial Analysis

    Stock Snapshot:

    • Current Price: $5.03
    • 52-Week Range: $1.69 – $5.07
    • Market Cap: $774.32M
    • P/E Ratio: -13.55
    • EPS (TTM): -$0.37
    • Revenue (TTM): $182.68 million

    Financial Highlights – Q2 (Dec 2024) Report:

    • Revenue: $60.099 million (35.39% YoY growth)
    • Net Income: -$5.11 million (61.81% YoY improvement)
    • Diluted EPS: -$0.03
    • Cash & Equivalents: $71.62 million
    • Debt-to-Equity Ratio: -1.84

    Xeris has demonstrated strong revenue growth, fueled by increasing product adoption. However, profitability remains a challenge, primarily due to continued investments in R&D and operational expansion. The company’s financials indicate a steady trajectory toward reducing losses, a critical factor for investors evaluating long-term potential.

    Growth Drivers for XERS Stock in 2025

    Expanding Drug Pipeline

    • Xeris is advancing multiple clinical trials targeting endocrinology, neurology, and metabolic disorders.
    • Potential FDA approvals and label expansions in 2025 could drive revenue growth.

    Strategic Partnerships & Licensing Deals

    • Collaborations with big pharma companies could unlock new revenue streams.
    • Licensing out its XeriSol™ and XeriJect™ platforms may generate milestone payments.

    Rising Demand for Ready-to-Use Injectables

    • The biopharmaceutical industry is shifting toward patient-friendly drug delivery methods.
    • Xeris’ innovative formulations provide a competitive edge over traditional injectable medications.

    Potential Risks & Challenges

    Regulatory & Clinical Trial Risks

    • Any delays or failures in FDA approvals could negatively impact stock performance.

    Financial Sustainability

    • Xeris is not yet profitable, relying on external funding and debt to support operations.

    Competition from Larger Biotech Firms

    • Companies like Eli Lilly (LLY) and Novo Nordisk (NVO) dominate the diabetes and endocrinology market.
    • Xeris must differentiate its products to capture market share.

    Analyst Ratings & Price Target Predictions

    XERS Recent Analyst Ratings: Strong Bullish Sentiment

    Analysts remain optimistic about Xeris Biopharma Holdings (XERS), with several firms raising their price targets and maintaining bullish ratings. The latest analyst ratings suggest strong growth potential, reflecting confidence in the company’s expanding product pipeline and revenue trajectory.

    Latest Analyst Ratings – March 7, 2025

    • Roanna Ruiz (Leerink Partners): Maintains an Outperform rating, raising the price target from $5.00 to $6.00, indicating potential upside.
    • Oren Livnat (HC Wainwright & Co.): Reiterates a Buy rating, with an aggressive price target jump from $6.60 to $8.00, reflecting strong conviction in Xeris’ growth outlook.
    • David Amsellem (Piper Sandler): Reiterates a Neutral rating, adjusting the price target from $3.00 to $4.00, signaling a cautious stance despite some upside.
    • Chase Knickerbocker (Craig-Hallum): Maintains a Buy rating, increasing the price target from $5.00 to $6.50, reinforcing a positive long-term outlook.

    The analyst consensus suggests a bullish trajectory for XERS stock, with multiple firms raising their price targets. While some remain cautious, the upward revisions indicate confidence in Xeris’ future performance, making it a compelling watchlist candidate for 2025.

    Institutional & Retail Investor Sentiment

    Institutional Ownership: Who’s Backing Xeris Biopharma (XERS)?

    Institutional investors play a crucial role in shaping market sentiment, and Xeris Biopharma Holdings (XERS) has gained solid backing from major financial institutions. Currently, 42.87% of XERS shares are held by institutional investors, reflecting strong confidence in the company’s prospects.

    Top Institutional Investors

    • Principal Financial Group Inc. leads the pack, holding 89.62K shares valued at $198.06K, representing a 0.06% stake in Xeris Biopharma.
    • AllianceBernstein L.P. follows closely, with 80.42K shares valued at $177.73K, also translating to a 0.06% stake in the company.

    Investor Sentiment on Xeris Biopharma (XERS) – What’s the Market Saying?

    Investor sentiment plays a critical role in determining short-term price movements, and Xeris Biopharma (XERS) stock has seen shifting sentiment trends over different timeframes.

    Short-Term Sentiment (1 Week & 1 Month)

    • The one-week sentiment score currently stands at 5.26, reflecting data from 22 social media posts but no news articles or opinion pieces.
    • This marks a significant decline of -15.78 points from 21.04 a week ago, indicating a drop in positive discussions surrounding XERS.
    • Over the past month, the sentiment trend has mirrored this movement, with the score falling from 21.04 to 5.26.
    • The sentiment score has fluctuated between 5.26 and 33.1 over the past month.

    Mid-Term Sentiment (6 Months)

    • The six-month sentiment score presents a more optimistic picture, currently at 39.2.
    • This figure is derived from 127 social media posts, 4 news articles, and 1 opinion article, reflecting higher investor engagement over the long term.
    • The sentiment score has ranged between 0 and 53.43, showing broad fluctuations in investor perception.

    The Verdict: Should You Buy, Hold, or Sell XERS Stock in 2025?

    With all the data analyzed—including financial performance, institutional ownership, sentiment trends, and analyst ratings—let’s break down whether Xeris Biopharma Holdings (XERS) stock is a buy, hold, or sell in 2025.

    Bullish Case: Why XERS Stock Could Be a Strong Buy

    Revenue Growth & Market Expansion
    Xeris reported strong YoY revenue growth of 35.39% in Q2 2024, indicating solid demand for its pharmaceutical products. Expanding partnerships and commercialization of innovative therapies could drive further revenue gains.

    Analyst Optimism & Price Target Upside
    Multiple analysts have maintained “Buy” or “Outperform” ratings on XERS stock, with price targets increasing from $5.00 to $8.00, indicating strong upside potential.

    Institutional Confidence
    Financial institutions hold 42.87% of XERS shares, with notable investors like Principal Financial Group and AllianceBernstein showing interest, which suggests institutional confidence in Xeris’ long-term growth.

    Potential for Profitability
    While Xeris still reports net losses, its reduced loss margins and higher gross revenue indicate the company is moving toward profitability. Continued cost management and revenue expansion could help Xeris break even sooner than expected.

    Bearish Case: Why XERS Stock May Face Challenges

    High R&D and Operating Costs
    Despite revenue growth, net losses remain a concern (-$5.11M in Q2 2024), primarily due to high research & development (R&D) and operational expenses. Investors should monitor whether Xeris can scale operations efficiently.

    Stock Volatility & Sentiment Decline
    Investor sentiment dropped significantly from 21.04 to 5.26 in one week, reflecting short-term uncertainty. This could indicate near-term price fluctuations and risk.

    Negative EPS & Valuation Concerns
    Xeris still has a negative EPS (-$0.03 diluted EPS) and a P/E ratio of -13.55, suggesting it is not yet profitable. The stock remains speculative for investors seeking consistent earnings.

    Final Recommendation: Buy, Hold, or Sell?

    • Buy if you are a long-term investor willing to tolerate volatility and believe in Xeris’ growth trajectory, revenue expansion, and future profitability.
    • Hold if you are waiting for profitability improvements and cost reductions before making a stronger commitment.
    • Sell if you prioritize stable, dividend-paying stocks or want to avoid speculative biotech investments.

    Conclusion: Is XERS Stock a Good Buy in 2025?

    Given Xeris Biopharma’s impressive revenue growth, strong analyst support, and institutional confidence, the stock presents an attractive long-term opportunity. However, its ongoing losses and stock volatility make it a riskier short-term investment. Investors seeking high-growth potential may consider buying, while those preferring stable returns should wait for further financial improvements.

  • Here’s Top 25 Biotech Stocks For September 2020

    Here’s Top 25 Biotech Stocks For September 2020

    One thing constant in the world is change. As time passes there are many industries that are undergoing changes as they expand their businesses and bring new innovations. One of the industries that are known for their constant change is the biotechnology industry.

    The biotech industry is continuously changing in every aspect of daily existence with new technological breakthroughs and advancements in knowledge. Companies are constantly striving to bring new medicines and vaccines to deal with the diagnosis.

    Let’s have a look at the top 25 biotech companies which are continuously adding new trends in the market:

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares were trading up 171.59% at $34.22 at the time of writing on Monday.

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) share price went from a low point around $10.09 to briefly over $37.00 in the past 52 weeks, though shares have since pulled back to $34.22. AIMT market cap has remained high, hitting $2.13B at the time of writing, giving it a price-to-sales ratio of more than 3550.

    If we look at the recent analyst rating AIMT, Cowen initiated coverage on AIMT shares with an Outperform rating. Aimmune Therapeutics recently disclosed it has signed an agreement with Nestle S.A. As per the agreement, Nestle will pay $34.50 per share in an all-cash transaction.

    Akcea Therapeutics Inc. (AKCA) last closed at $18.28, in a 52-week range of $8.00 to $22.79. It has been disclosed yesterday that Ionis Pharmaceutical has bought the 24% shares of Akcea it hasn’t owned earlier for $18.15 per share in cash. This acquisition is one step forward to make a strong and efficient organization that gives benefits to all shareholders.

    Capricor Therapeutics Inc. (NASDAQ: CAPR) Shares headed rising, higher as much as 14.64% after Capricor Therapeutics to Present at The LD 500 Virtual Conference. Capricor market capitalization is 115.11 million. The most recent rating by Maxim Group, on December 26, 2018, is at a Hold.

    Capricor Therapeutics, a clinical-stage biotechnology company has disclosed earlier that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for a Phase 2 clinical trial of CAP-1002 in COVID-19 patients.

    Apellis Pharmaceuticals Inc. (APLS) stock soar by 14.74% to $30.83. The most recent rating by ROTH Capital, on July 20, 2020, is at a Buy. Its stock fluctuated between the 52-weeks low range of $16.85 and a 52-weeks high range of $45.04. It has moved up 82.97% from its 52-weeks low and moved down -31.55% from its 52-weeks high.

    Xeris Pharmaceuticals Inc. (NASDAQ: XERS) rose 10.71% after gaining more than $0.45 on Monday. Xeris, a specialty pharmaceutical company disclosed August 26, 2020, that the Compensation Committee of Xeris’ Board of Directors awarded non-qualified stock options for an aggregate of 500 share of its common stock to 1 new employee under the Inducement Equity Plan of Xeris.

    Xeris share price went from a low point around $1.42 to briefly over $12.29 in the past 52 weeks, though shares have since pulled back to $4.71. It has traded up $231.34% from its 52-weeks low and has traded down -61.72% from its 52-weeks high.

    9 Meters Biopharma Inc. (NASDAQ: NMTR) shares headed rising, higher as much as 7.73%. It has disclosed Monday that it has decided to form the scientific advisory board (SAB). The SAB includes an acclaimed group of six experts in the gastroenterology field with sub-specialties in celiac disease, inflammatory bowel disease (IBD), and functional GI diseases. 9 Meters have gained +0.05 during its trading on Monday. It has moved up 76.17% and moved down -49.46% from its 52-weeks low and high range, respectively.

    VBI Vaccines Inc. (NASDAQ: VBIV) rose 6.77% after gaining more than $0.27 on Monday. VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020. During the presentation, Professor of Paediatrics at the University of Bristol, UK, and principal investigator of the CONSTANT Phase 3 clinical study, Adam Finn, M.D., Ph.D., revealed the encouraging points of hepatitis B antibodies. VBI Vaccines traded up 815.15% from its 52-weeks low and traded down -38.53% from its 52-weeks high.

    CymaBay Therapeutics Inc. (NASDAQ: CBAY) rose 5.37% after gaining more than $0.33 on Monday. It has disclosed the result of Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). The data presented at electronic presentation showed the safety and efficacy of seladelpar over 1 year of open level treatment. These findings suggest that seladelpar treatment in a high-risk PBC patient population promotes clinically significant improvement.

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) rose 4.53% after gaining more than $0.18 on Monday. BioCryst Inc disclosed Monday it has received Orphan Drug Desigantion from FDA for its oral Factor D inhibitor, BCX9930. It is used for the treatment paroxysmal nocturnal hemoglobinuria (PNH). It has moved up as its announced it has received the $44 million  National Institute of Allergy and Infectious Diseases (NIAID). This amount is awarded to BCRX by NIAID to support the development of galidesivir.

    ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Shares headed rising, higher as much as 4.24%. The most recent rating by Raymond James, on August 25, 2020, is at an Outperform. ACADIA Inc has announced earlier that it has bought CerSci Therapeutics.

    Immunomedics Inc. (IMMU) stock soar by 6.37% to $44.56. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Immunomedics stock has fluctuated between the 52-weeks low and high range of $8.80-$44.91, respectively.

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) last closed at $114.22, in a 52-week range of $72.67 to $121.50. Analysts have a consensus price target of $141.47.

    Seres Therapeutics Inc. (NASDAQ: MCRB) stock soar by 8.21% to $26.49.  It has moved upward 951.19% from its 52-weeks low and moved down -19.73% from its 52-weeks high. The most recent rating by Piper Sandler, on August 18, 2020, is at an Overweight.

    Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) last closed at $29.51 after gaining +2.54 on Monday. It has a 52-week range of $12.99 to $27.97. It has moved up 127.17% and 5.51% from its 52-weeks low and high, respectively. Analysts have a consensus price target of $32.88.

    Geron Corporation (NASDAQ: GERN) Shares headed rising, higher as much as 6.22%. The most recent rating by Stifel, on August 03, 2020, is at a Buy.

    Sesen Bio Inc. (NASDAQ: SESN) rose 6.19% after gaining more than $0.06 on Monday. SESN’s stock has changed between the 52-weeks low range of $0.37 and a high range of $1.52. It has moved up and moved down 178.38%, -33.12% from its 52-weeks low and high, respectively.

    Kadmon Holdings Inc. (NYSE: KDMN) last closed at $5.00, in a 52-week range of $2.04 to $5.50. It has traded up 145.10% from its 52-weeks low and traded down -9.09% from its 52-weeks high. Looking at its liquidity, its current ratio is 6.20.

    Evofem Biosciences Inc. (EVFM) stock soar by 6.07% to $3.32 after Evofem Biosciences to Participate in Four Upcoming Investor Conferences. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Equal-weight.

    MacroGenics Inc. (NASDAQ: MGNX) Shares headed rising, higher as much as 6.01%. The most recent rating by Citigroup, on August 03, 2020, is at a Neutral.

    Iovance Biotherapeutics Inc. (NASDAQ: IOVA) last closed at $33.33, in a 52-week range of $17.67 to $41.49. Analysts have a consensus price target of $47.08.

    Surface Oncology Inc. (NASDAQ: SURF) stock soar by 5.01% to $6.50. The most recent rating by Wedbush, on August 28, 2020, is at an Outperform.

    Fortress Biotech Inc. (NASDAQ: FBIO) Shares headed rising, higher as much as 4.63% after LD Micro — 360 Companies Set to Present this Week. The most recent rating by B. Riley FBR, on December 18, 2019, is at a Buy.

    Synthetic Biologics Inc. (SYN) last closed at $0.64, in a 52-week range of $0.25 to $0.75. It has moved up 153.17% from its 52-weeks low and moved down -14.87% from its 52-weeks high.

    Zogenix Inc. (NASDAQ: ZGNX) stock soar by 4.37% to $23.67. The most recent rating by Raymond James, on August 25, 2020, is at an Mkt perform. ZGNX has traded up and down 42.16% and -58.63% from its 52-weeks low and high range.

    Dynavax Technologies Corporation (NASDAQ: DVAX) rose 4.18% after gaining more than $0.24 on Monday. Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference.